Tag: Peter Loftus

Moderna Is Testing Its Covid-19 Vaccine on Young Children

Mary Pat Campbell

Link: https://www.wsj.com/articles/moderna-is-testing-its-covid-19-vaccine-on-young-children-11615892416

Excerpt:

Moderna Inc. has begun studying its Covid-19 vaccine in children aged 6 months to 11 years in the U.S. and Canada, the latest effort to widen the mass-vaccination campaign beyond adults.

The Cambridge, Mass., company said Tuesday that the first children have received doses in the study, which Moderna is conducting in collaboration with the National Institute of Allergy and Infectious Diseases and a division of the Department of Health and Human Services.

“This pediatric study will help us assess the potential safety and immunogenicity of our COVID-19 vaccine candidate in this important younger age population,” Moderna Chief Executive Stéphane Bancel said.

Author(s): Peter Loftus

Publication Date: 16 March 2021

Publication Site: Wall Street Journal

J&J Covid-19 Vaccine Shipments Head for States

Mary Pat Campbell

Link: https://www.wsj.com/articles/j-j-covid-19-vaccine-to-start-arriving-as-soon-as-tuesday-u-s-administration-says-11614603239

Excerpt:

The U.S. Food and Drug Administration on Saturday authorized use of the J&J vaccine. The drug company had made nearly four million doses for initial shipment. The administration said it expected about 20 million doses to be delivered by the end of March.

Distribution will be uneven early on as the company increases production, it said, meaning the bulk of the additional 16 million doses will arrive later in the month.

“We’re getting these doses out the door as soon as they’re available to ensure vaccines get into arms as quickly as possible,” a senior Biden administration official said Sunday.

Author(s): Peter Loftus and Ken Thomas

Publication Date: 1 March 2021

Publication Site: Wall Street Journal

Moderna Says Covid-19 Vaccine for South Africa Strain Is Ready for Human Testing

Mary Pat Campbell

Link: https://www.wsj.com/articles/moderna-says-covid-19-vaccine-for-south-africa-strain-is-ready-for-human-testing-11614201000

Excerpt:

Moderna Inc. said it has made the initial batch of doses of a new Covid-19 vaccine designed to better protect people against a new strain of the coronavirus that has shown some resistance to the company’s original vaccine.

The Cambridge, Mass., company on Wednesday said it shipped the new shots to the National Institutes of Health to conduct the first human study of the variant vaccine, which could start within weeks.

The new vaccine, code-named mRNA-1273.351, is designed to better match the virus variant that was first identified in South Africa but has since spread elsewhere.

Moderna, which makes the second Covid-19 shot authorized in the U.S., might be the first vaccine maker to have finished the laboratory work of designing a shot targeting variants that started spreading swiftly late last year.

Author(s): Peter Loftus

Publication Date: 24 February 2021

Publication Site: Wall Street Journal